The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin's Lymphoma in Second Complete or Partial Remission

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 4, 2007, Pages 486-492

  Lerner, Rachel E ^a   Thomas, William ^b   DeFor, Todd E ^c   Weisdorf, Daniel J ^a,c   Burns, Linda J ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Autologous hematopoietic stem cell transplantation; International Prognostic Index; Non Hodgkin's lymphoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW METASTASIS; CANCER REGRESSION; CANCER RELAPSE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PREDICTION; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; STEM CELL MOBILIZATION; WHOLE BODY RADIATION;

ADULT; AGE FACTORS; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33947260232     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.12.452     Document Type: Article

References (26)

1. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1002-1006
2. Gordon L.I., Harrington D., Anderson J., et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327 (1992) 1342-1349
3. Armitage J.O. Treatment of non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1023-1030
4. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
6. Vose J.M., Rizzo D.J., Jing T.W., et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 10 (2004) 116-127
7. Prince H.M., Imrie K., Crump M., et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haemat 92 (1996) 880-889
8. Wheeler C., Strawderman M., Ayash L., et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustustine, and etoposide. J Clin Oncol 11 (1993) 1085-1091
9. Gugliemi C., Martelli M., Federico M., et al. Risk assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. Haematologica 86 (2001) 941-950
10. Blay J., Gomez F., Sebban C., et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 92 (1998) 3562-3568
11. Hamlin P.A., Zelenetz A.D., Kewalrami T., et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102 (2003) 1989-1996
12. Jabbour E., Peslin N., Arnaud P., et al. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation. Leuk Lymphoma 46 (2005) 861-867
13. Caballero M.D., Pérez-Simón J.A., Iriondo A., et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 14 (2003) 140-151
14. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Arlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
15. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17 (1999) 1244-1253
16. Rosenberg S.A. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 61 (1977) 1023-1027
17. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
19. Cox D. Regression models and life-s. J R Stat Soc [B] 34 (1972) 187-220
20. Philip T., Armitage J.O., Spitzer G., et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316 (1987) 1491-1498
21. Bosly A., Sonet A., Salles G., et al. Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: a randomized study from the GELA: LNH RP 93. Blood 90 Suppl 1 (1997) 594a
22. Kewalramani T., Zelenetz A.D., Hedrick E.E., et al. High-dose chemotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 96 (2000) 2399-2404
23. Vose J.M., Sharp G., Chan W.C., et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 20 (2002) 2344-2352
24. Salar A., Sierra J., Gandarillas M., et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 27 (2001) 405-412
25. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.
26. Gopal A.K., Gooley T.A., Golden J.B., et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 27 (2001) 593-599